University of Kansas Medical Center

  • Image

    University of Kansas Medical Center

    Frontiers transcends disciplines to seek innovation and improvement in healthcare by supporting the researchers of today and tomorrow.
  • Shelby Williams, BSN, RN, has been named the Director of Clinical and Translational Science Unit (CTSU) Rainbow at the University of Kansas Medical Center, effective July 6, 2021. Williams will direct the operations at CTSU Rainbow and supervise the CTSU nursing and research staff. She will also serve as a resource for the other Frontiers CTSUs at KUMC Fairway, KU Wichita, and Children's Mercy
  • Community health workers and health equity teams across Kansas have partnered with the University of Kansas Medical Center to launch a multimedia campaign "Community Health Workers Beat the Virus" in seven different languages to encourage COVID-19 testing and vaccination among under-resourced populations. This initiative is part of the Rapid Acceleration of Diagnostics for Underserved Populations

  • Vasculitis Clinical Research Consortium

    Vasculitis refers to a group of rare diseases that involve inflammation of blood vessels, which disrupts blood flow and often causes damage to the body’s organs. The cause of most forms of vasculitis remains unknown, and treatments involve the use of strong medications that can have serious side effects. The Vasculitis Clinical Research Consortium (VCRC) is an international, multicenter clinical

  • Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe)

    Amyotrophic lateral sclerosis (ALS) is a fatal disease that involves progressive death of motor nerves in the brain, brainstem and spinal cord. The disease is closely related to disorders such as primary lateral sclerosis, hereditary spastic paraplegia, progressive muscular atrophy and frontotemporal dementia. These diseases have shared genetic causes and underlying biology. They also have in

  • University of Kansas Medical Center

    AZD1222 is being developed for the prevention of COVID-19. AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein, commonly known as the “Oxford vaccine” or as “ChAdOx.” We describe a “scale up” approach utilizing CTSA resources to conduct a multisite clinical trial testing a COVID vaccine in the midst of a pandemic incorporating at

  • Frontiers: University of Kansas Clinical and Translational Science Institute is looking for a Project Manager to help organize and submit our renewal application and become an integral part of the team. This person will work with a senior team of researchers and clinicians and will be responsible for managing the renewal process along with other project management responsibilities. This position

  • If there is one thing the coronavirus pandemic has made clear, it's the necessity of translating, as quickly as possible, the discoveries made in medical laboratories into actual treatments, procedures and diagnostic tools that can help patients. Frontiers: University of Kansas Clinical and Translational Science Institute has awarded three one-year $50,000 pilot grants to help scientists studying

  • Mario Castro, MD, MPH, has been named the Principal Investigator and Director of Frontiers: University of Kansas Clinical and Translational Science Institute, effective June 1, 2020. In this role, Castro will lead, manage and shape the strategic direction of the clinical and translational research enterprise throughout the Kansas City region and across the state. "As a clinical translational

  • Kansas City Quality and Value Innovation Consortium Logo
    University of Kansas Medical Center

    The Kansas City Quality and Value Innovation Consortium (KC QVIC) is hosting an online forum on Thursday, June 4, for healthcare leaders from across the metro to discuss how healthcare has changed due to the COVID-19 pandemic.

  • The JUNTOS Center for Advancing Latino Health at KU Medical Center, whose mission is to eliminate health disparities in under-served Latino communities in Kansas, has been working hard to deliver COVID-19 information to Kansas City's Spanish-speaking communities in their native language. In the Kansas City area, nearly 6% of the population speak Spanish as their primary language. In Wyandotte

  • Drawing of a network on a global

    With an emphasis on educational issues and a goal of sharing resources, best practices and facilitating collaboration, members of the Midwest Consortium (MC) partner to strengthen clinical research education programs, mentoring, and career development opportunities for scholars. The Midwest Consortium for education and research collaboration began in 2006 with three Roadmap K12 institutions

  • Greater Plains Collaborative Clinical Data Research Network Logo

    The Greater Plains Collaborative (GPC) is a network of 12 leading medical centers in eight states committed to a shared vision of improving healthcare delivery through ongoing learning, adoption of evidence-based practices, and active research dissemination. GPC builds on strong research programs at individual sites, existing community engagement and informatics infrastructures and data warehouses

  • Drawing of a network on a global

    The Consortium of Rural States (CORES) was formed to facilitate collaborative and disciplined efforts that will produce new opportunities for advancing translational research. The Collaborative comprises Arkansas, Kansas, New Mexico and Utah, states that share common health care challenges, including significant rural populations. Each state is served by a single Clinical and Translational

  • A new research unit that will greatly expand the capacity for scientists to conduct clinical trials is set to open at the University of Kansas Medical Center on Jan. 13. It will be the first clinical and translational science unit (CTSU) on the main KU Medical Center campus in Kansas City, Kansas. The new CTSU Rainbow builds on the success of the CTSUs in Fairway, Kansas, the KU School of Medicine

  • University of Kansas Medical Center
    A Blue Ribbon taskforce convened in 2005 concluded that in order to effectively advance medical care in a region, “a strong translational research enterprise needed to be developed which could take basic discoveries from the laboratories, translate them into drugs and therapeutic devices, manage animal testing and clinical trials, and get them in the hands of groups that can advance them to market